Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:orphan drug
go back to main search page
Accession:CHEBI:71031 term browser browse the term
Definition:Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease.
Synonyms:related_synonym: orphan drugs
 xref: PMID:20036435;   PMID:20800761;   PMID:21180460;   PMID:21682893;   PMID:21947805;   PMID:22363762;   PMID:22366309;   PMID:22371464;   PMID:22731105;   PMID:22739138;   PMID:22747423;   PMID:22814659;   PMID:22814660;   PMID:22973866;   PMID:22981668;   PMID:22989856;   PMID:23013790;   PMID:23090701;   PMID:23109143;   PMID:23129684;   Wikipedia:Orphan_drug


show annotations for term's descendants           Sort by:
 
4-aminopyridine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra1b adrenoceptor alpha 1B multiple interactions EXP 4-Aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine] CTD PMID:18480251 NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP 4-Aminopyridine results in increased expression of BAX mRNA CTD PMID:24378259 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression EXP 4-Aminopyridine results in decreased expression of BIRC2 mRNA CTD PMID:24378259 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression EXP 4-Aminopyridine results in decreased expression of BIRC3 mRNA CTD PMID:24378259 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Bmf Bcl2 modifying factor increases expression EXP 4-Aminopyridine results in increased expression of BMF mRNA CTD PMID:24378259 NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084
JBrowse link
G Casp3 caspase 3 increases activity EXP 4-Aminopyridine results in increased activity of CASP3 protein CTD PMID:24378259 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity EXP 4-Aminopyridine results in increased activity of CASP7 protein CTD PMID:24378259 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp9 caspase 9 increases activity EXP 4-Aminopyridine results in increased activity of CASP9 protein CTD PMID:24378259 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cd40 CD40 molecule increases expression EXP 4-Aminopyridine results in increased expression of CD40 mRNA CTD PMID:24378259 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd40lg CD40 ligand increases expression EXP 4-Aminopyridine results in increased expression of CD40LG mRNA CTD PMID:24378259 NCBI chr  X:159,703,703...159,714,886
Ensembl chr  X:159,703,578...159,716,562
JBrowse link
G Ctsb cathepsin B increases expression EXP 4-Aminopyridine results in increased expression of CTSB mRNA CTD PMID:24378259 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Dpysl4 dihydropyrimidinase-like 4 increases expression EXP 4-Aminopyridine results in increased expression of DPYSL4 mRNA CTD PMID:24378259 NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
JBrowse link
G Gad2 glutamate decarboxylase 2 increases expression
multiple interactions
EXP 4-Aminopyridine results in increased expression of GAD2 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]
CTD PMID:25917026 NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
JBrowse link
G Galnt5 polypeptide N-acetylgalactosaminyltransferase 5 decreases expression EXP 4-Aminopyridine results in decreased expression of GALNT5 mRNA CTD PMID:24378259 NCBI chr 3:44,025,964...44,072,073
Ensembl chr 3:44,025,300...44,074,678
JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D multiple interactions ISO [Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein CTD PMID:19911010 NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
JBrowse link
G Hdac5 histone deacetylase 5 multiple interactions EXP [Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein CTD PMID:15773917 NCBI chr10:90,140,183...90,169,853
Ensembl chr10:90,140,183...90,151,042
JBrowse link
G Jph3 junctophilin 3 increases expression EXP 4-Aminopyridine results in increased expression of JPH3 mRNA CTD PMID:24378259 NCBI chr19:54,553,419...54,613,477
Ensembl chr19:54,553,419...54,613,477
JBrowse link
G Kcna10 potassium voltage-gated channel subfamily A member 10 multiple interactions ISO 4-Aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of Potassium] CTD PMID:10836990 NCBI chr 2:209,920,590...209,932,665
Ensembl chr 2:209,920,590...209,932,665
JBrowse link
G Kcnd3 potassium voltage-gated channel subfamily D member 3 increases expression
multiple interactions
EXP 4-Aminopyridine results in increased expression of KCND3 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA]
CTD PMID:25917026 NCBI chr 2:207,923,775...208,140,727
Ensembl chr 2:207,923,775...208,140,727
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO 4-Aminopyridine results in decreased activity of KCNH2 protein CTD PMID:19915712 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kcnip1 potassium voltage-gated channel interacting protein 1 decreases expression
increases expression
multiple interactions
EXP 4-Aminopyridine results in decreased expression of KCNIP1 mRNA
4-Aminopyridine results in increased expression of KCNIP1 mRNA
KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased abundance of gamma-Aminobutyric Acid]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA]
CTD PMID:24378259, PMID:25917026 NCBI chr10:18,558,128...18,942,677
Ensembl chr10:18,558,128...18,942,540
JBrowse link
G Mag myelin-associated glycoprotein decreases expression EXP 4-Aminopyridine results in decreased expression of MAG mRNA CTD PMID:24378259 NCBI chr 1:89,345,325...89,360,905
Ensembl chr 1:89,345,429...89,360,733
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha increases expression EXP 4-Aminopyridine results in increased expression of MAP1LC3A mRNA CTD PMID:24378259 NCBI chr 3:150,801,289...150,802,935
Ensembl chr 3:150,801,289...150,802,935
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]
4-Aminopyridine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]
CTD PMID:19911010, PMID:22759588, PMID:28132918 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]
4-Aminopyridine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]
CTD PMID:19911010, PMID:22759588, PMID:28132918 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Ncor2 nuclear receptor co-repressor 2 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein] CTD PMID:15773917 NCBI chr12:36,871,917...37,033,701
Ensembl chr12:36,871,999...37,033,701
JBrowse link
G Olr1583 olfactory receptor 1583 decreases expression EXP 4-Aminopyridine results in decreased expression of OLR1583 mRNA CTD PMID:24378259 NCBI chr13:91,725,324...91,726,265
Ensembl chr13:91,725,324...91,726,265
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions EXP [Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]] CTD PMID:15773917 NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
JBrowse link
G RGD1311517 similar to RIKEN cDNA 9430015G10 increases expression EXP 4-Aminopyridine results in increased expression of C1ORF159 mRNA CTD PMID:24378259 NCBI chr 5:173,542,058...173,559,761
Ensembl chr 5:173,542,358...173,559,761
JBrowse link
G S100a7a S100 calcium binding protein A7A decreases expression EXP 4-Aminopyridine results in decreased expression of S100A7A mRNA CTD PMID:24378259 NCBI chr 2:190,058,093...190,063,132
Ensembl chr 2:190,058,093...190,062,534
JBrowse link
G Syn1 synapsin I affects response to substance
multiple interactions
increases response to substance
increases expression
ISO
EXP
SYN1 protein affects the susceptibility to 4-Aminopyridine
ciproxifan inhibits the reaction [4-Aminopyridine results in increased expression of SYN1 protein modified form]
SYN1 results in increased susceptibility to 4-Aminopyridine
CTD PMID:22759588, PMID:28132918 NCBI chr  X:1,321,315...1,379,202
Ensembl chr  X:1,321,315...1,379,198
JBrowse link
G Traf2 Tnf receptor-associated factor 2 increases expression EXP 4-Aminopyridine results in increased expression of TRAF2 mRNA CTD PMID:24378259 NCBI chr 3:2,746,061...2,770,690
Ensembl chr 3:2,746,075...2,770,620
JBrowse link
carglumic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atg5 autophagy related 5 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of ATG5 mRNA] CTD PMID:31369747 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Becn1 beclin 1 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 protein] CTD PMID:31369747 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B protein] CTD PMID:31369747 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 protein] CTD PMID:31369747 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
ivacaftor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity
ISO [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; [ivacaftor results in increased activity of CFTR protein mutant form] which affects the transport of Sodium; [ivacaftor results in increased activity of CFTR protein mutant form] which results in increased secretion of Chlorides
ivacaftor results in increased activity of CFTR protein; ivacaftor results in increased activity of CFTR protein mutant form
CTD PMID:19846789, PMID:21083385, PMID:21602569, PMID:32374624 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
ixazomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Lat2 linker for activation of T cells family, member 2 multiple interactions ISO ixazomib inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein]; ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein] CTD PMID:23001822 NCBI chr12:25,114,099...25,128,381
Ensembl chr12:25,119,355...25,125,749
JBrowse link
lumacaftor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Capn1 calpain 1 multiple interactions ISO CAPN1 protein affects the reaction [lumacaftor binds to CFTR protein mutant form] CTD PMID:31324722 NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
affects folding
ISO [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; calpain inhibitor 2 promotes the reaction [lumacaftor binds to and affects the folding of CFTR protein mutant form]; CAPN1 protein affects the reaction [lumacaftor binds to CFTR protein mutant form]; lumacaftor binds to and affects the folding of CFTR protein mutant form
lumacaftor affects the folding of CFTR protein mutant form
CTD PMID:31324722, PMID:32374624 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
macitentan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A decreases expression ISO macitentan results in decreased expression of ABCB1 mRNA CTD PMID:28369585 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression ISO macitentan results in decreased expression of ABCC2 mRNA CTD PMID:28369585 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 decreases expression ISO macitentan results in decreased expression of ABCC3 mRNA CTD PMID:28369585 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression ISO macitentan results in decreased expression of SLC10A1 mRNA CTD PMID:28369585 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
rifaximin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA
CTD PMID:21141967, PMID:22790967 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA CTD PMID:22790967 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA CTD PMID:22790967 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] CTD PMID:21599020 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein CTD PMID:22790967 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cfd complement factor D multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA CTD PMID:22790967 NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA CTD PMID:22790967 NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA CTD PMID:22790967 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein CTD PMID:22790967 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein CTD PMID:22790967 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA CTD PMID:22790967 NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
JBrowse link
G Fabp2 fatty acid binding protein 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein CTD PMID:22790967 NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
JBrowse link
G Ifng interferon gamma multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] CTD PMID:21599020 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein CTD PMID:21599020 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Lta lymphotoxin alpha multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA CTD PMID:22790967 NCBI chr20:4,851,889...4,854,677
Ensembl chr20:4,852,496...4,854,677
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] CTD PMID:21599020 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein CTD PMID:22790967 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
increases expression
increases response to substance
ISO 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin
CTD PMID:21599020, PMID:22291955, PMID:22790967, PMID:27506419, PMID:30408883 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA CTD PMID:22790967 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein CTD PMID:21599020 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:21599020 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
torasemide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen increases expression EXP Torsemide results in increased expression of AGT protein modified form CTD PMID:18154949 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Cyp11b3 cytochrome P450, family 11, subfamily b, polypeptide 3 affects expression EXP Torsemide affects the expression of CYP11B2 protein CTD PMID:18001696 NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 affects metabolic processing EXP CYP2C11 protein affects the metabolism of Torsemide CTD PMID:15890479 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing
multiple interactions
ISO CYP2C8 protein results in increased metabolism of Torsemide
Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein]
CTD PMID:15304522 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Nppa natriuretic peptide A decreases expression EXP Torsemide results in decreased expression of NPPA protein CTD PMID:18154949 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions EXP Torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein] CTD PMID:7954537 NCBI chr19:34,408,275...34,761,003
Ensembl chr19:34,448,289...34,752,695
JBrowse link
G Ren renin increases expression EXP Torsemide results in increased expression of REN protein CTD PMID:7954537 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Slc12a2 solute carrier family 12 member 2 decreases activity
multiple interactions
ISO Torsemide results in decreased activity of SLC12A2 protein
Torsemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]
CTD PMID:29959396 NCBI chr18:52,917,124...52,985,281
Ensembl chr18:52,917,124...52,985,261
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases expression
affects expression
EXP Torsemide results in decreased expression of TGFB1 protein
Torsemide affects the expression of TGFB1 protein
CTD PMID:18001696, PMID:18154949 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      application 19426
        pharmaceutical 19301
          drug 19301
            orphan drug 71
              4-aminopyridine + 41
              ACT-333679 + 0
              Orkambi 0
              carglumic acid 4
              isavuconazole 0
              isavuconazonium sulfate 0
              ivacaftor + 1
              ixazomib + 1
              ixazomib citrate 0
              lenvatinib 0
              lenvatinib mesylate 0
              lumacaftor + 2
              macitentan 4
              rifaximin 21
              selexipag 0
              sodium phenylbutyrate 0
              uridine triacetate 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.